# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Martin Luther (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RE004-SYN
- Date: 2026-07-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ottilie Brandt-Mensah, MD
- Calendar frame: modern shifted

## What we are working on

- He is frightened of another attack, especially while preaching or teaching, and of losing the hearing in his left ear **S**
- He has felt low and abandoned for weeks and wonders whether the attacks are a spiritual trial rather than an illness **S**
- He remembers the pain of the stone last year and wants to avoid another **S**

## Your goals

- Fewer and milder vertigo attacks: no more than one disabling attack a month by three months, and able to preach without fear of an attack. Target: 2026-10-27. Recorded outcome: One attack between the second and six-week visits and none in the five weeks before the thirteen-week visit; preaching again. **S**
- Depression response (PHQ-9 down by at least 50 percent) by three months. Target: 2026-10-27. Recorded outcome: PHQ-9 6 at thirteen weeks, down 60 percent from 15. **S**
- Sodium intake below 2,300 mg a day. Target: 2027-01-31. Recorded outcome: 24-hour urine sodium 140 mmol (about 3,200 mg) at thirteen weeks: improved but above target. **S**
- Urine volume of at least 2.5 liters a day. Target: 2027-01-31. Recorded outcome: 24-hour urine volume 1.6 liters at thirteen weeks. **S**

## What we agreed to do

- Otology (neurotology) consultation in two weeks, with audiometry, to confirm the cause of the attacks and plan treatment. Guideline: Clinical Practice Guideline: Ménière's Disease (2020) **S**
- Diagnostic work-up at intake: ear and neurological examination, positional testing, blood count, kidney function and electrolytes, calcium, uric acid, TSH and urinalysis; a symptom diary of each attack (start, duration, hearing, tinnitus, ear fullness, headache, light sensitivity); formal audiometry at the otology visit. Guideline: Clinical Practice Guideline: Ménière's Disease (2020); Diagnostic criteria for Menière's disease (2015); Vestibular migraine: diagnostic criteria (update) (2022) **S**
- Meclizine only for severe attacks, for no more than three days at a time; sit or lie down at the first warning; no driving, ladders or swimming alone while attacks are active. Guideline: Clinical Practice Guideline: Ménière's Disease (2020) **S**
- Depression: PHQ-9 at every visit, a structured diagnostic interview at the next visit, and a safety plan with the 988 Suicide & Crisis Lifeline and the clinic number. Guideline: Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024) **S**
- Stone history: drink enough water to pass at least 2.5 liters of urine a day; serum calcium and uric acid at intake; stone analysis and metabolic testing if another stone occurs. Guideline: Medical Management of Kidney Stones: AUA Guideline (2014) **S**
- Ménière disease: education; sodium 1,500 to 2,300 mg a day; caffeine and alcohol limited; hydrochlorothiazide 25 mg daily as maintenance, with sodium and potassium checked at the next visit; no betahistine; MRI of the internal auditory canals with gadolinium; repeat audiogram at about three months; intratympanic steroid held in reserve if disabling attacks continue after three months. Guideline: Clinical Practice Guideline: Ménière's Disease (2020); Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial) (2016) **S**
- Recurrent depression: weekly cognitive behavioral therapy with behavioral activation, and sertraline 25 mg daily for a week, then 50 mg, by shared decision; sodium checked on sertraline with the thiazide. Guideline: Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Right ureteral stone: naproxen for pain, tamsulosin as medical expulsive therapy for up to four weeks, urine strained and the stone sent for analysis, and renal ultrasound after passage. Guideline: Medical Management of Kidney Stones: AUA Guideline (2014); Surgical Management of Stones: American Urological Association/Endourological Society Guideline, Part I (2016) **S**
- Vestibular rehabilitation for unsteadiness between attacks: a home program taught by a vestibular physical therapist. Guideline: Clinical Practice Guideline: Ménière's Disease (2020) **S**
- Stone prevention from the 24-hour urine: fluids to at least 2.5 liters of urine a day, sodium restriction with a dietitian, normal dietary calcium, citrus fruit for citrate, thiazide continued, and a repeat 24-hour urine in about six months. Guideline: Medical Management of Kidney Stones: AUA Guideline (2014) **S**

## Follow-up

- 2026-07-28: New patient visit for attacks of vertigo with left-ear tinnitus and muffled hearing, and low mood: history, neurological and ear examination, blood and urine tests, depression and safety screening, and an otology referral **S**
- 2026-08-11: Two-week review and otology consultation with audiometry; diagnoses of Ménière disease and recurrent depression **S**
- 2026-09-08: Periodic adult preventive visit **S**
- 2026-09-22: Six-week review: attacks, MRI result, thiazide and sertraline safety, mood, and the passed stone **S**
- 2026-10-27: Thirteen-week review: attacks, repeat audiogram, mood, and the 24-hour urine for stone prevention **S**

This teaching document does not replace care from a qualified clinician.
